UIC Researchers Uncover a Revolutionary Target to Combat Metastatic Cancer
The University of Illinois Chicago (UIC) has made a groundbreaking discovery in the fight against cancer, shedding light on a novel approach to tackle metastatic cancer. Researchers have identified a molecular switch, KCNMB1, which plays a pivotal role in determining the physical properties of cancer cells, offering a promising therapeutic target.
In a study published in the journal Developmental Cell, the UIC team delves into the intriguing relationship between cancer cell physics and metastasis. The lead researcher, Ekrem Emrah Er, highlights the counterintuitive nature of cancer, where the outer shell of a tumor appears rigid, yet the individual cells within it are remarkably soft and flexible. This softness is a double-edged sword, allowing cancer cells to leak and disseminate, while also making them resistant to immune cell attacks.
Er explains, "The immune system struggles to shatter soft cancer cells like a ceramic plate. Instead, they bounce off, remaining intact and capable of metastasis." This discovery challenges the conventional understanding of cancer cell behavior, as scientists have long observed that metastatic cancer cells are softer than their healthy counterparts.
The research team's investigation led them to KCNMB1, an ion channel protein that regulates potassium ion movement across cell membranes. By activating this pathway, they successfully increased cell stiffness, making cancer cells more susceptible to immune cell attacks. This finding is particularly exciting as ion channels are already well-studied and targeted by existing drugs, facilitating the translation of these findings into potential therapies.
Alexa Gajda, a postdoctoral fellow and recent doctoral graduate from UIC, emphasizes the convenience of this discovery. She notes that drugs targeting ion channels are already in use for cardiovascular and stroke treatments, providing a head start in the development of cancer therapies. The team's experiments with a potassium-channel activator, BMS-204352, demonstrated reduced distant tumor growth and enhanced immune cell activity in animal models of metastatic breast cancer.
This study also reveals the intricate interplay between potassium levels and cancer cell behavior. Tumors create environments rich in potassium, which can soften cancer cells and suppress immune responses. By activating the potassium channel, the researchers successfully reversed these effects, restoring stiffness and improving immune cell activity.
While further research is necessary before clinical trials, this discovery opens up a new avenue in the battle against cancer metastasis. Er concludes, "We now have a biophysical front to combat cancer, offering a fresh perspective on treatment strategies."
This research highlights the importance of understanding the intricate relationship between cancer cell physics and metastasis, paving the way for innovative therapeutic approaches. As the scientific community continues to explore these avenues, the future of cancer treatment looks increasingly promising.
